Researchers have sequenced a Chinese hamster ovary (CHO) cell line to support improvements to biopharm protein production.
Significant improvements to yields are unlikely but sequencing the genome for CHO-K1 still gives researchers “another tool in the bioprocessing toolbox”. In particular, cell line engineering could benefit from the information.
“The CHO-K1 genomic sequence will facilitate the design of targeted genetic manipulations to aid in cell line engineering…and allow for more comprehensive deployment of 'omic tools for CHO-K1 and related cell lines”, said the researchers in a paper published in Nature Biotechnology .
China-based BGI and US-based GT Life Sciences collaborated on sequencing the genome.